EMEA-003642-PIP01-24
Submitted by Anonymous (not verified) on 22 October 2025 - 14:50
EMEA-003642-PIP01-24
EMEA-003643-PIP01-24
Submitted by Anonymous (not verified) on 22 October 2025 - 14:45
EMEA-003643-PIP01-24
Human medicines European public assessment report (EPAR): Livtencity, maribavir, Date of authorisation: 09/11/2022, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 22 October 2025 - 14:45
Human medicines European public assessment report (EPAR): Livtencity, maribavir, Date of authorisation: 09/11/2022, Revision: 7, Status: Authorised
Highlights – EMA/ EASD bilateral meeting
Submitted by Anonymous (not verified) on 22 October 2025 - 14:08
Highlights – EMA/ EASD bilateral meeting
Human medicines European public assessment report (EPAR): Insulin Human Rechon, insulin human, Status: Application withdrawn
Submitted by Anonymous (not verified) on 22 October 2025 - 14:05
Human medicines European public assessment report (EPAR): Insulin Human Rechon, insulin human, Status: Application withdrawn
EMEA-003646-PIP01-24
Submitted by Anonymous (not verified) on 22 October 2025 - 13:34
EMEA-003646-PIP01-24
EMEA-003648-PIP01-24
Submitted by Anonymous (not verified) on 22 October 2025 - 13:26
EMEA-003648-PIP01-24
EMEA-003649-PIP01-24
Submitted by Anonymous (not verified) on 22 October 2025 - 13:21
EMEA-003649-PIP01-24
EMEA-003656-PIP01-24
Submitted by Anonymous (not verified) on 22 October 2025 - 13:19
EMEA-003656-PIP01-24
Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 22 October 2025 - 11:30
Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 10, Status: Authorised